免疫活化DC联合CIK治疗晚期结直肠癌的临床研究  

Activated DC combined with CIK immunotherapy for patients with advanced colorectal cancer

作　　者：芮韬 吴国清[3] 徐继[1] 郑爱红[3] 吴浩[1] 叶再元[1] 

机构地区：[1]浙江省人民医院胃肠外科,杭州研究生310014 [2]浙江省中医院胃肠外科 [3]浙江省人民医院肿瘤内科,杭州310014

出　　处：《浙江医学》2015年第18期1505-1509,共5页Zhejiang Medical Journal

基　　金：浙江省"十二五"重大科技专项(2012C13015-1);浙江省医药卫生平台资助计划(2012RCA004)

摘　　要：目的观察免疫活化树突状细胞(IbC)联合细胞因子诱导的杀伤细胞(CIK)治疗(DC-CIK治疗)晚期结直肠癌的临床疗效。方法选取2010年以来的IV期结直肠癌患者90例,随机分为两组,联合治疗组患者采用免疫活化DC-CIK治疗,同时行化疗,单纯化疗组患者仅行化疗。比较两组患者的生存率、免疫功能变化,并判断免疫活化DC-CIK治疗的安全性。结果联合治疗组2年及3年总生存率均明显高于单纯化疗组(2年总生存率67.6%vs 38.3%,3年总生存率29-8%vs 18.8%,均P<0.05)。单纯化疗组患者治疗后CD8^+细胞比例高于治疗前(P<0.05);与单纯化疗组治疗后比较,联合治疗组治疗后CD4^+、CD4^+/CD8^+、CD16^+CD56^+细胞比例升高,CD8^+细胞比例明显下降,且联合治疗组治疗前后CD4^+、CD4^+/CD8^+、CD16^+CD56^+细胞比例亦有变化(均P<0.05)。结论免疫活化DC-CIK治疗对晚期结直肠癌患者有较好的临床疗效,可改善患者的免疫抑制状态,且具有良好的安全性。Objective To evaluate the efficacy of activated DC-CIK adjuvant immunotherapy for patients with advanced colorectal cancer. Methods Ninety patients with stage IV colorectal cancer were randomly assigned to receive DC-CIK immunotherapy plus chemotherapy （n=45, combined therapy group） or chemotherapy alone （n=45, chemotherapy group）. The survival status, immune function and adverse effects were compared between two groups. Results Compared with chemother- apy group, the 2- and 3-year overall survival （OS） rate in combined therapy group was significantly improved （67.6% vs 38.3%, P〈0.05; 29.8% vs 18.8%, P〈0.05, respectively）. After combined therapy, the mean CD4＋ level, CD4＋/CD8＋ ratio, CD16＋CD56＋ level were increased and the mean CD8＋ level decreased compared with those before combined therapy. No serious adverse ef- fects were observed in 116 course of activated DC-CIK immunotherapy. Conclusion Activated DC-CIK adjuvant immunothera- py is effective for advanced colorectal cancer patients, which is associated with improved immune function of patients.

关 键 词：免疫治疗 结直肠癌 活化 总生存时间 

分 类 号：R735.34[医药卫生—肿瘤]